Compare Amphastar Pharmaceuticals Inc (AMPH) vs First Trust NASDAQ Cybersecurity ETF (CIBR) Price & Performance

AMPH trades at $22.93, down 1.08% on the day, with a bullish technical signal from moving averages and strong trend strength. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q4 2025 and Q1 2026, with revenue growth supported by new product launches. Valuation ratios appear reasonable with a P/E of 13.57 and EV/EBITDA of 7.12, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.

The outlook is cautious due to recent earnings misses and a Zacks Strong Sell rating, though the Wells Fargo conference presentation may boost visibility. Risks include FDA warning letters and generic drug tariff pressures, but the shift to proprietary drugs offers growth potential. Analysts are mostly neutral with a consensus price target of $20.75, below the current price.

CIBR, the First Trust NASDAQ Cybersecurity ETF, trades at $94.01, down 0.61% on the day. Technical indicators show a neutral to bearish short-term picture, with the overall signal neutral but moving averages bearish. The ETF holds leading cybersecurity stocks like Palo Alto Networks and CrowdStrike, benefiting from strong sector demand driven by AI adoption and increasing cyber threats. Recent news highlights the fund's improved portfolio structure and thematic focus.

The outlook for CIBR is supported by robust cybersecurity spending trends, with global expenditure forecast to exceed $300 billion in 2026. However, stretched valuations of top holdings and sector concentration risks warrant caution. The ETF offers diversified exposure to a high-growth theme, but investors should monitor valuation levels and competitive dynamics in the cybersecurity space.